leisure time -WSS

leisure time

author：hotspot 2025-09-29 22:53:13 - browse：6

Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022 — Photo illustration: STAT; Photo: Adobe

Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.

Lin alleges in a lawsuit that prominent oncologist Padmanee Sharma derailed the publication of papers based on Lin’s work, threatened to undermine her fledgling career, and made defamatory comments about her in retaliation for resisting making Sharma an author on a paper and saying the senior researcher had made no substantial contribution to it.

“Having this and another paper taken — what would’ve been important papers for my career,” Lin told STAT in an interview. “I’m sure that my career in research has just fallen off a cliff.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Wikipedia

WSS

Unmasking the 'centricity' illusion in clinical trials

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

What Congress can do to address the rural doctor shortage

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Thermo Fisher plant for manufacturing gene therapies to expand

J&J reports mixed data on next

explore

leisure time

entertainment

In Memoriam: Notable people who died in 2023

Microbiome research is starting to find links to chronic diseases

Walensky prepares to leave CDC — and Congress — behind

Stroke rates rising, especially in working

Hollywood unions extend contract negotiations for actors

Pharma’s losing bet in New Jersey

Psychedelics group wrestles with new pharma identity

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Medical records are filled with copy

FDA panel to weigh approval of NurOwn, controversial ALS drug

hotspot

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Emergency workers more likely to restrain Black patients: study

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

CDC's new outbreak response network to include Northeastern

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Ozempic cut risk of death in diabetes patients with chronic kidney disease

focus

knowledge

Wikipedia

leisure time